Rapamycin Effects on Gut Inflammation and Microbiome in HLA-B27 Rats

Results from a preclinical study where HLA-B27 transgenic rats with gut inflammation were treated with rapamycin or vehicle for 5 weeks. The study includes transcriptome analysis of colon tissue, microbiome analysis of cecal contents, and qPCR measurements of pro-inflammatory cytokine expression from isolated immune cells. Sample size, row count, and column count are not specified in the input.

Use Cases

• Analyze transcriptome data from colon tissue to identify changes in expression of pro-inflammatory cytokines like Il17a, Il17f, and Tnf following rapamycin treatment.
• Compare cecum microbiome profiles between rapamycin-treated and vehicle-treated HLA-B27 rats to identify shifts in microbiota associated with inflammation.
• Correlate stool and colon histological scores with cytokine expression levels from qPCR data to model the relationship between clinical symptoms and molecular markers.
• Investigate the differential effect of rapamycin on the gut microbiome in wild-type rats versus HLA-B27 transgenic rats using microbiome analysis data.

Strengths

• Includes multiple data modalities: transcriptome analysis, microbiome analysis, histological scoring, and qPCR cytokine measurements.
• Experimental design includes both HLA-B27 transgenic rats and wild-type controls treated with rapamycin or vehicle for a 5-week period.
• Data is associated with a specific, peer-reviewed research objective investigating rapamycin's effect on HLA-B27-mediated inflammation.

Limitations

• The dataset is small in file size (826.0 KB), suggesting it may contain summary or processed results rather than raw, high-volume sequencing data.
• Sample size (number of biological replicates) is not specified, limiting statistical power assessment.
• Data is derived from a single preclinical rat model, which may not directly translate to human spondyloarthritis.

Provenance

Source

Figshare, authored by Jinny Van Doorn.

Collection Method

Generated from a controlled laboratory experiment involving treatment of HLA-B27 transgenic rats, followed by transcriptomic, microbiome, and qPCR analyses.

Time Range

The experimental treatment period was 5 weeks; specific calendar dates are not provided.

Freshness

Last updated March 20, 2026.